Tags

Type your tag names separated by a space and hit enter

Mass spectrometric identification of human phosphate cytidylyltransferase 1 as a novel calcium oxalate crystal growth inhibitor purified from human renal stone matrix.
Clin Chim Acta. 2009 Oct; 408(1-2):34-8.CC

Abstract

BACKGROUND

A relatively small number of well-characterized inhibitors of kidney stone formation have been identified from the previous research involved in its formation. In this study conventional biochemical methods have been combined with recent advances in mass spectrometry (MS) to identify a novel calcium oxalate (CaOx) crystal growth inhibitor in human renal stone matrix.

METHODS

Proteins were isolated from the matrix of human CaOx containing kidney stones. Proteins having MW>10 kDa were subjected to anion exchange and molecular-sieve chromatography. Protein fractions were tested for their effects on CaOx crystal growth. Most potent fraction P2' was excised, in-gel tryptic digested and identified by matrix assisted laser desorption/ionization-time of flight (MALDI-TOF) MS.

RESULTS

An anionic protein (MW approximately 42 kDa) with potent inhibitory activity against CaOx crystal growth was purified. Its homogeneity was confirmed by RP-HPLC. It was identified by MALDI-TOF-MS followed by database search on MASCOT server as human phosphate cytidylyltransferase 1, beta. Molecular weight of this novel CaOx crystal growth inhibitor from human renal stone matrix is also the same as that of human phosphate cytidylyltransferase 1, choline, beta.

CONCLUSIONS

Human phosphate cytidylyltransferase 1, choline, beta is a novel CaOx crystal growth inhibitor. It is involved in the biosynthesis of phosphatidylcholine which happens to be an important constituent of human renal stones and is also reported to have an antilithiatic effect.

Authors+Show Affiliations

Biotechnology & Bioinformatics, Jaypee University of Information Technology, Waknaghat, H.P., India.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19595683

Citation

Priyadarshini, , et al. "Mass Spectrometric Identification of Human Phosphate Cytidylyltransferase 1 as a Novel Calcium Oxalate Crystal Growth Inhibitor Purified From Human Renal Stone Matrix." Clinica Chimica Acta; International Journal of Clinical Chemistry, vol. 408, no. 1-2, 2009, pp. 34-8.
Priyadarshini , Singh SK, Tandon C. Mass spectrometric identification of human phosphate cytidylyltransferase 1 as a novel calcium oxalate crystal growth inhibitor purified from human renal stone matrix. Clin Chim Acta. 2009;408(1-2):34-8.
Priyadarshini, ., Singh, S. K., & Tandon, C. (2009). Mass spectrometric identification of human phosphate cytidylyltransferase 1 as a novel calcium oxalate crystal growth inhibitor purified from human renal stone matrix. Clinica Chimica Acta; International Journal of Clinical Chemistry, 408(1-2), 34-8. https://doi.org/10.1016/j.cca.2009.06.041
Priyadarshini , Singh SK, Tandon C. Mass Spectrometric Identification of Human Phosphate Cytidylyltransferase 1 as a Novel Calcium Oxalate Crystal Growth Inhibitor Purified From Human Renal Stone Matrix. Clin Chim Acta. 2009;408(1-2):34-8. PubMed PMID: 19595683.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mass spectrometric identification of human phosphate cytidylyltransferase 1 as a novel calcium oxalate crystal growth inhibitor purified from human renal stone matrix. AU - Priyadarshini,, AU - Singh,Shrawan Kumar, AU - Tandon,Chanderdeep, Y1 - 2009/07/10/ PY - 2009/05/25/received PY - 2009/06/29/revised PY - 2009/06/29/accepted PY - 2009/7/15/entrez PY - 2009/7/15/pubmed PY - 2009/12/23/medline SP - 34 EP - 8 JF - Clinica chimica acta; international journal of clinical chemistry JO - Clin Chim Acta VL - 408 IS - 1-2 N2 - BACKGROUND: A relatively small number of well-characterized inhibitors of kidney stone formation have been identified from the previous research involved in its formation. In this study conventional biochemical methods have been combined with recent advances in mass spectrometry (MS) to identify a novel calcium oxalate (CaOx) crystal growth inhibitor in human renal stone matrix. METHODS: Proteins were isolated from the matrix of human CaOx containing kidney stones. Proteins having MW>10 kDa were subjected to anion exchange and molecular-sieve chromatography. Protein fractions were tested for their effects on CaOx crystal growth. Most potent fraction P2' was excised, in-gel tryptic digested and identified by matrix assisted laser desorption/ionization-time of flight (MALDI-TOF) MS. RESULTS: An anionic protein (MW approximately 42 kDa) with potent inhibitory activity against CaOx crystal growth was purified. Its homogeneity was confirmed by RP-HPLC. It was identified by MALDI-TOF-MS followed by database search on MASCOT server as human phosphate cytidylyltransferase 1, beta. Molecular weight of this novel CaOx crystal growth inhibitor from human renal stone matrix is also the same as that of human phosphate cytidylyltransferase 1, choline, beta. CONCLUSIONS: Human phosphate cytidylyltransferase 1, choline, beta is a novel CaOx crystal growth inhibitor. It is involved in the biosynthesis of phosphatidylcholine which happens to be an important constituent of human renal stones and is also reported to have an antilithiatic effect. SN - 1873-3492 UR - https://www.unboundmedicine.com/medline/citation/19595683/Mass_spectrometric_identification_of_human_phosphate_cytidylyltransferase_1_as_a_novel_calcium_oxalate_crystal_growth_inhibitor_purified_from_human_renal_stone_matrix_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-8981(09)00348-9 DB - PRIME DP - Unbound Medicine ER -